MNPR
Monopar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$96.47
−6.07%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 115.12x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.95x
- Price / sales
- —
- Price / cash flow
- -0.20x
Enterprise value
- Enterprise value
- $513.3M
- EV / sales
- —
- EV / EBITDA
- -27.75x
- EV / EBIT
- -23.21x
- Market cap
- $647.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026